J&J says FDA rejects Risperdal as autism treatment

Johnson & Johnson said on Friday U.S. regulators rejected its application to market antipsychotic drug Risperdal for patients with autism.

Johnson & Johnson’s Pharmaceutical Research & Development unit said it received a “not-approvable” letter from the U.S. Food and Drug Administration on its petition for an additional use of the drug, which currently is used as a treatment for schizophrenia.

J&J said given the lack of treatments for autism, it will evaluate the letter and determine the appropriate next steps.

In April, the FDA ordered new warnings on all antipsychotic drugs, including Risperdal, to alert physicians to a higher death rate when the medicines are prescribed for atypical use for treating dementia in elderly patients.

J&J’s shares fell 3 cents to $67.38 in Friday trade on the New York Stock Exchange. 

Print Version
Tell-a-Friend

RELATED ARTICLES:

Domestic violence may raise kids’ abuse risk   Cascading effect of even minor early problems may explain serious teen violence   Personal rehab helpful for multiple sclerosis   Holidays Don’t Have to be Difficult for People with an Eating Disorder   PTSD Symptoms Linked to Increased Risk of Death After Heart Events   Response rates to antidepressants differ among English- and Spanish-speaking Hispanics   US smokers increasingly hooked on nicotine   The woman in red drives the men crazy, study finds   Spanking may make kids aggressive   Psychological Study Reveals That Red Enhances Men   Anti-inflammatory medications may become a treatment for schizophrenia   Boston Medical Center researchers educating chief residents about addiction